A new treatment built from immune cells in the blood could be key to a quick, adaptable and low-risk way to heal wounds ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK 's new drug application (NDA) for Blenrep ...

Vera believes atacicept is positioned for best-in-class potential, targeting B cells and plasma cells to reduce autoantibodies ... s product candidates, strategy, and regulatory matters. Because such ...

Q2 2024 Earnings Call Transcript September 12, 2024 Operator: Thank you for standing by, and welcome to the Innate Pharma ...

The ID3 gene maintains FOXP3 expression, which is necessary for maintaining the suppressive function of regulatory T cells. The PRDM1 gene encodes the B lymphocyte–induced maturation protein–1 ...

In this thought leader article Orjana Terova, Melisa Carpio, Ian Flaherty, Robin Butler, Nico Tuason, and Christine Gebski from Repligen describe how disruptive technologies are improving efficiency ...

Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline ...

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss ...